C4U is a bio-venture company originated from The University of Osaka, established in 2018 for the practical application of the novel genome editing technology CRISPR-Cas3 technology.CRISPR-Cas3 technology has strengths, such as its ability to induce large-scale deletions of DNA, its superior safety profile due to less concern about off-target deletion expression, and its freedom to operate (FTO) under patents.C4U is establishing this technology as a genome editing platform that enables both knock-out and knock-in, and is expected to be utilised in a wide range of fields, including medicine, biotechnology, agriculture and fisheries, and the environmental sector.
Location: Japan
Investors 1
| Date | Name | Website |
| - | JIC Ventur... | j-vgi.co.j... |
Mentions in press and media 4
| Date | Title | Description |
| 14.12.2023 | C4U and Celide Therapeutics sign joint research agreement to realize hematopoietic stem cell gene therapy products | - |
| 14.12.2023 | C4U and Celide Therapeutics sign joint research agreement to realize hematopoietic stem cell gene therapy products | Ceride Therapeutics Co., Ltd. C4U and Celide Therapeutics sign joint research agreement to realize hematopoietic stem cell gene therapy products …… C4U Co., Ltd. (Headquarters: Suita City, Osaka Prefecture, Representative Director: Akimitsu... |
| 07.11.2023 | Healiva teams up with Japanese biotech to develop therapies for genetic skin disorders | |
| 08.08.2023 | Kansai’s Deep Tech Startups Lead the Charge in Japan’s Startup Development | In November 2022, Japan announced the “Startup Development Five-year Plan”. This ambitious national initiative aims to invest 10 trillion yen in startups, create 100,000 startups and foster 100 unicorns by 2027. A key area of focus is the c... |